Lv11
20 积分 2023-09-17 加入
Type 1 Receptor Tyrosine Kinase Profiles Identify Patients With Enhanced Benefit From Anthracyclines in the BR9601 Adjuvant Breast Cancer Chemotherapy Trial
9小时前
已完结
Trastuzumab after primary treatment for early stage HER2-positive breast cancer reduces recurrence
9小时前
已完结
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
12天前
已完结
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial
2个月前
已完结
Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update
3个月前
已完结
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up
3个月前
已完结
Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial
3个月前
已完结
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
4个月前
已完结
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
4个月前
已完结
Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for EarlyTOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial
4个月前
已完结
皖公网安备34019202002308
